Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
P2X3 receptor antagonism attenuates the progression of heart failure.
Lataro RM, Moraes DJA, Gava FN, Omoto ACM, Silva CAA, Brognara F, Alflen L, Brazão V, Colato RP, do Prado JC Jr, Ford AP, Salgado HC, Paton JFR. Lataro RM, et al. Among authors: ford ap. Nat Commun. 2023 Mar 28;14(1):1725. doi: 10.1038/s41467-023-37077-9. Nat Commun. 2023. PMID: 36977675 Free PMC article.
The discovery and development of gefapixant.
Ford AP, Dillon MP, Kitt MM, Gever JR. Ford AP, et al. Auton Neurosci. 2021 Nov;235:102859. doi: 10.1016/j.autneu.2021.102859. Epub 2021 Jul 31. Auton Neurosci. 2021. PMID: 34403981
The inevitability of ATP as a transmitter in the carotid body.
Bardsley EN, Pen DK, McBryde FD, Ford AP, Paton JFR. Bardsley EN, et al. Among authors: ford ap. Auton Neurosci. 2021 Sep;234:102815. doi: 10.1016/j.autneu.2021.102815. Epub 2021 May 7. Auton Neurosci. 2021. PMID: 33993068
P2X3 receptor antagonism reduces the occurrence of apnoeas in newborn rats.
Katayama PL, Abdala AP, Charles I, Pijacka W, Salgado HC, Gever J, Ford AP, Paton JFR. Katayama PL, et al. Among authors: ford ap. Respir Physiol Neurobiol. 2020 Jun;277:103438. doi: 10.1016/j.resp.2020.103438. Epub 2020 Apr 5. Respir Physiol Neurobiol. 2020. PMID: 32259688 Free PMC article.
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, Li YP, Wu WC, Xu ZJ, Muccino DR, Ford AP; Protocol 012 Investigators. Smith JA, et al. Among authors: ford ap. Lancet Respir Med. 2020 Aug;8(8):775-785. doi: 10.1016/S2213-2600(19)30471-0. Epub 2020 Feb 25. Lancet Respir Med. 2020. PMID: 32109425 Clinical Trial.
110 results